Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Fineline Cube Jul 2, 2026
Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Fineline Cube Jul 1, 2026
Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Fineline Cube Jul 1, 2026
Company Drug

Hansoh Pharmaceutical Secures Exclusive Rights to QYuns Therapeutics’ QX004N in Greater China

Fineline Cube May 6, 2024

Jiangsu QYuns Therapeutics Co., Ltd, a biopharmaceutical company based in China, has entered into a...

Company Deals Medical Device

Well Lead Medical’s Stone Removal Sheath Gains Karl Storz as US Sole Agent

Fineline Cube May 6, 2024

Well Lead Medical Co., Ltd (SHA: 603309), a Guangzhou-based specialist in medical catheters, has entered...

Company

Shenzhen Hepalink Logs 5.55% Q1 Revenue Growth and 133% Net Profit Increase

Fineline Cube May 6, 2024

Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced its financial results for the...

Company

Zhejiang Hisun Pharmaceutical’s Ex-President Li Yan Investigated for Graft

Fineline Cube May 6, 2024

Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a Chinese pharmaceutical company, has announced that Li...

Company Drug

Jacobio Pharma’s Glecirasib Shows Promise in Phase II Study for NSCLC Presented at ASCO

Fineline Cube May 6, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the presentation of...

Company Drug

BeiGene’s Anti-PD-1 Therapy Tislelizumab Expands Indication for Gastric Cancer in China

Fineline Cube May 6, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that its anti-PD-1 therapy, tislelizumab, has...

Company Medical Device Policy / Regulatory

China’s National Procurement Office Announces Continuous VBP for Joint Prosthetics

Fineline Cube May 6, 2024

The National High-Value Medical Consumables Joint Procurement Office in China has initiated a new round...

Company Drug

China’s NMPA Approves Shenzhen Chipscreen’s Chidamide for DLBCL Indication

Fineline Cube May 6, 2024

Shenzhen Chipscreen Biosciences Co., Ltd, a biopharmaceutical company based in China, announced that it has...

Company Deals

Siemens Healthineers AG Partners with Haidian District Government to Boost Medical Innovation in Beijing

Fineline Cube May 6, 2024

Siemens Healthineers AG (ETR: SHL), a leading medical technology company based in Germany, has entered...

Company

Hainan Poly Pharm’s Manufacturing Units Get GMP Nod From Saudi Food and Drug Authority

Fineline Cube May 6, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, announced that it has...

Policy / Regulatory

GBA Center of NMPA Launches Filing Guidance for Pharmaceutical Enterprises

Fineline Cube Apr 30, 2024

The Guangdong-Hong Kong-Macau Greater Bay Area (GBA) Center for Drug Evaluation and Inspection, under the...

Company Drug

Keymed Biosciences’ IL-4Rα Monoclonal Antibody for Allergic Rhinitis Accepted by China NMPA

Fineline Cube Apr 30, 2024

China-based biopharmaceutical company Keymed Biosciences Inc. (HKG: 2162) has announced that the National Medical Products...

Company Drug

Bristol-Myers Squibb’s Camzyos Approved by China’s NMPA for Hypertrophic Cardiomyopathy Treatment

Fineline Cube Apr 30, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has received marketing approval from China’s National Medical Products Administration...

Company Drug

Cutia Therapeutics Submits New Drug Application for Androgenic Alopecia Treatment in Hong Kong

Fineline Cube Apr 30, 2024

Cutia Therapeutics (HKG: 2487), a dermatology-focused pharmaceutical company, has announced the submission of a New...

Company Drug

Zhejiang Huahai Pharmaceutical Wins IND Approval for Antibody-Drug Conjugate from China’s NMPA

Fineline Cube Apr 30, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced that it...

Company R&D

German Study Highlights Potential of Amgen’s Blinatumomab in Treating Rheumatoid Arthritis

Fineline Cube Apr 30, 2024

Researchers from Germany’s University of Erlangen-Nuremberg have unveiled promising clinical data on the use of...

Company Legal / IP

U.S. Judge Dismisses Johnson & Johnson and Bristol-Myers Squibb Lawsuits Against Drug-Pricing Provisions in Inflation Reduction Act

Fineline Cube Apr 30, 2024

In a recent legal development, a U.S. federal court judge has rejected the legal challenges...

Company Deals

Sino Biological Inc. to Acquire Canadian Bioactive Enzyme Manufacturer SignalChem Biotech

Fineline Cube Apr 30, 2024

Sino Biological Inc. (SHE: 301047), a leading provider of biological research reagents and technical contract...

Policy / Regulatory

China’s Q1 2024 Pharma Trade Registers 6.3% Growth Amid Global Recovery

Fineline Cube Apr 30, 2024

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company

Dizal Pharmaceutical’s Sunvozertinib Logs RMB 91.29 Million in Sales Following EGFR Inhibitor Approval

Fineline Cube Apr 30, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China, has announced that its...

Posts pagination

1 … 390 391 392 … 689

Recent updates

  • Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics
  • Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC
  • Bio-heart Secures NMPA Approval for Bioheart Biodegradable Drug-Eluting Stent – First Fully Absorbable Coronary Stent in China
  • Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification
  • Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Company Deals

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Others

Bio-heart Secures NMPA Approval for Bioheart Biodegradable Drug-Eluting Stent – First Fully Absorbable Coronary Stent in China

Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.